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Abstract 
Targeted metabolomics requires accurate and precise quantification of candidate biomarkers, often 
through tandem mass spectrometric (MS/MS) analysis. Differential isotope labeling (DIL) improves 
mass spectrometric (MS) analysis in metabolomics by derivatizing metabolites with two isotopic forms 
of the same reagent. Despite its advantages, DIL-liquid chromatographic (LC)-MS/MS can result in 
substantial increase in workload when fully validated quantitative methods are required. To decrease 
the workload, we hypothesized that single point calibration or relative quantification could be used as 
alternative methods. Either approach will result in significant saving in resources and time. To test our 
hypothesis, six urinary metabolites were selected as model compounds. Urine samples were analyzed 
using a fully-validated multipoint dansyl chloride-DIL-LC-MS/MS method. Samples were reprocessed 
using single point calibration and relative quantification modes. Our results demonstrated that the 
performance of single point calibration or relative quantification was inferior, for some metabolites, to 
multipoint calibration. The lower limit of quantification failed in the quantification of ethanolamine in 
most of participant samples using single point calibration. In addition, its precision was not acceptable 
in one participant during serine and ethanolamine quantification. On the other hand, relative 
quantification resulted in the least accurate data. In fact, none of the data generated from relative 
quantification for serine was comparable to that obtained from multipoint calibration. Finally, while 
single point calibration showed an overall acceptable performance for the majority of the model 
compounds, we cannot extrapolate the findings to other metabolites within the same analytical run. 
Analysts are advised to assess accuracy and precision for each metabolite in which single point 
calibration is the intended quantification mean.  
 
Keywords: metabolomics; single point calibration; validation; quantification; differential isotope 
labeling, dansyl chloride  
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1. Introduction 
Metabolomics encompasses the identification and quantification of all possible endogenous and 
exogenous metabolites in a biological sample [1-3]. Biomarker discovery is a key application in 
metabolomics that aims to improve disease diagnosis and prognosis while also assessing therapeutic 
efficacy and toxicity [1-4]. Metabolomics studies flow sequentially from untargeted to targeted 
platforms [5-7]. Unlike screening in the untargeted approach, targeted quantification of preselected 
metabolites requires a robust methodology usually with multiple reaction monitoring (MRM) 
acquisition [6,8,5,7]. Targeted analysis is typically conducted by coupling tandem mass spectrometry 
(MS/MS) to gas chromatography (GC) or liquid chromatography (LC) [6,8,5,7]. 
The lack of well-established analytical frameworks for absolute quantification is a bottleneck in 
the biomarker qualification process [9-13]. Contrary to method validation for xenobiotics, available 
guidelines [14,15] are not well suited to address all challenges with endogenous metabolite 
quantification. Consequently, there has been confusion on the extent of method validation needed to 
meet regulatory requirements [9-12]. A “fit-for-the-purpose” approach, achieving minimum validation 
criteria, has been deemed adequate for preliminary biomarker discovery experiments. However, 
methods designated for clinical decision making require full validation to ascertain accuracy, precision, 
specificity, robustness and stability [9-12].  
In comparison with multipoint calibration, single point calibration involves the use of a single 
reference solution for the quantification of the target analyte. It assumes that the response of the analyte 
and the detector is linear to the analyte’ s concentration and the hypothetical calibration curve has a zero 
y-intercept [16,17]. Single point calibration has been frequently used [18-25] and it represents a 
compromise between validation rigidity, workload and speed of data acquisition, thus providing semi-
quantitative data [18]. Inaccuracies from single point calibration have been reported, citing low analytes 
concentration [19] or nonlinear calibration models [20], as possible reasons. On the contrary, it has 
demonstrated comparable performance to multipoint calibration  for quantifying analytes in biological 
fluids [21-23], pharmaceutical preparations [24] and tissue extracts [25,22].  
Differential isotope labeling (DIL) in metabolomics, pioneered by L. Li, has been exploited to 
address many typically encountered challenges, including matrix interference and internal standard 
availability [26-28]. Using DIL, the derivatizing reagent is synthesized into light and heavy (deuterium 
or 13C-labeled) forms [29,27,30,28,31-35]. The simultaneous derivatization of the analyte with both 
forms generates two isotopologue products that when mixed are detected as a peak pair by mass 
spectrometry (MS) [29,33,27,34,32,28,31,30]. Derivatizing reagents targeting specific 
submetabolomes, such as dansyl chloride (DNS-Cl) (alcohols, amines and phenols) [27,29], p-
dimethylaminophenacyl bromide (acids) [28,30], dansyl hydrazine (carbonyl) [31] and 
bromoacetonylquinolinium bromide (thiols) [32] are continuously introduced to DIL technique, 
increasing its usefulness in metabolomics. DIL is used for both absolute and semi quantification 
purposes (Figure 1) [29,33,30,27,34,32,28,35,31]. However, absolute quantification [28,35-37] has 
been an unfavorable option for researchers seeking rapid quantitative metabolomics data. This can be 
attributed to the additional workload for optimizing different reaction conditions along with the routine 
optimization of chromatographic/MS systems and the extensive validation needed prior to sample 
analysis [15,14]. Accordingly, DIL has been mostly exploited in semi quantification, or “relative 
quantification” as described within the metabolomics society (Figure 1) [27,32].   
We have recently developed an LC-MS/MS method for the absolute quantification of 19 amine- 
and phenol- containing urinary metabolites using DIL with 12C2/13C2- DNS-Cl [37]. The method was 
fully validated according to regulatory guidelines [14,15]. However, a typical batch for clinical data 
acquisition would necessitate around 28 non-patient injections (around 11 hours) of calibration 
3 
 
standards, quality control (QC) samples, blanks and system suitability samples [38,37], leading to an 
increased analysis time. Accordingly, we decided to pursue a comparative study between three different 
quantification modes using DIL-LC-MS/MS, where the performance of single point calibration or 
relative quantification was compared to the validated multipoint calibration method [37]. We 
hypothesized that these methods could provide accurate and precise analytical data, which would 
subsequently result in significant reduction in the required resources for high throughput targeted DIL-
LC-MS/MS metabolomics. However, our hypothesis was not accurate for the entire set of metabolites 
selected for this study and the opposite was proven true. This work represents the first comparison of 
the analytical performance of three DIL-based targeted methods for metabolomics application. 
2. Experimental 
 
2.1. Materials and reagents  
12C2/13C2- DNS-Cl were synthesized as previously described [37]. All reagents and reference 
standards are detailed in our recent work [37].   
 
2.2. Urine sample collection 
Participants (n=7) were enrolled after obtaining their written informed consent as approved by 
the University of Saskatchewan’s biomedical research ethics board (Bio# 13-89). Random mid-stream 
urine samples were collected from healthy male participants (25-40 years of age) currently not taking 
any form of medications. Urine specimen cups (Starplex Scientific Inc, ON, CA) were frozen at -80 ºC 
shortly after collection and samples were subjected to 1 freeze-thaw cycle in which they divided into 
aliquots in 1.5 mL micro centrifuge tubes (Fischer, CA). A pooled urine sample was prepared by mixing 
equal aliquots from 5 participants.  
 
2.3. Standards derivatization  
The preparation of underivatized individual standards, underivatized working standards mixture 
and derivatized standards mixture was done as previously reported [37]. Briefly, for the derivatized 
standards, i.e. 12C2-DNS-analytes stock solution preparation; 50 µL from the working stock solution of 
the 19 standards were mixed with 30 µL bicarbonate/carbonate buffer (pH 9.4, 0.5 M) and 40 µL 12C2-
DNS-Cl (10.13 mg/mL in acetonitrile (ACN)). The mixture was heated at 60 ºC for 30 minutes and 
excess DNS-Cl was quenched with 10 µL 0.25 M NaOH with further heating at 60 ºC for 10 min. 
Seventy µL of 300 mM FA in 50% ACN were added for medium acidification [37]. These derivatization 
steps, with the use of the appropriate isotopic form of DNS-Cl, are common between 12C2-DNS-
analytes, 13C2-DNS-ISs and 12C2/13C2- urine samples.  
Only for the preparation of 13C2-DNS-ISs stock solution, used in multipoint and single point 
calibrations, the addition of 300 mM FA in 50% ACN was followed by further dilution with 50 µL of 
50% ACN. This dilution step was previously optimized in order to achieve the validated concentration 
of the ISs in the final mixtures [37]. Ten µL aliquots from the aforementioned solution were used for 
spiking purposes in single and multipoint calibrations [37]. We have previously validated the suitability 
of the “surrogate urine” in simulating real derivatized urine [37]. The surrogate urine is used for the 
preparation of multipoint calibration standards and QC samples and it is prepared following the same 
derivatization steps described for 12C2-DNS analytes solution. However, 50 µL of pooled urine sample 
(7 patients) were used instead of the working stock solution and 30 µL ACN substituted the derivatizing 
reagent [37]. This matrix is meant to compensate for the absence of metabolite-free urine needed for 
method validation.  
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For relative quantification, only 12C2-DNS-analytes solution is needed and was prepared similar 
to multipoint calibration. The produced 12C2-DNS-analytes solution was further mixed with equal 
volume from 13C2-DNS-pooled urine prepared as described below.  
 
2.4. Urine derivatization 
Urine aliquots were thawed to room temperature, diluted two-fold with ACN, vortexed and 
centrifuged at 13,000 rpm for 10 min prior to derivatization. Multipoint and single point quantification 
required the preparation of 12C2-urine samples [37]. Fifty µL of the supernatant solution of each urine 
sample (7 participants and one pooled urine sample) were derivatized as described for 12C2-DNS 
analytes solution. Following the addition of 300 mM FA in 50% ACN, 50 µL of each reacted urine 
mixture were diluted with 50 µL 50% ACN containing 10 µL 13C2-DNS-ISs. The solutions were 
transferred into HPLC vials equipped with 100 µL glass inserts for analysis [37]. For relative 
quantification, additional 13C2- pooled urine was prepared. After the addition of 300 mM FA in 50% 
ACN in 12C2-urine or 13C2- pooled urine, equal portions of both isotopic solutions were mixed for HPLC 
analysis.  
 
2.5. Instrumentation 
The validated method developed in our previous work [37] has been partially validated on a 
1290 Agilent UPLC system (Mississauga, ON, Canada) interfaced to an AB Sciex 6500 API QTRAP 
instrument (AB Sciex, Concord, ON, Canada). A 1290 Agilent autosampler set at 4 ºC was used to 
deliver 5 µL samples for separation on a Kinetex C18 column (100 mm×2.1 mm, 5 µm ID, 100 Å pore 
size, Phenomenex, Canada), maintained at 22 ºC. The binary mobile phase system, composed of (A) 
5% acetonitrile (ACN) in 0.1% formic acid (FA) and (B) 0.1% FA in ACN, was used for metabolites 
separation in 25 min. At a flow rate of 250 µL/min, the gradient system was as follows; t=0, 90% A, 
t=6, 85% A, t=19, 35% A, t=20, 35% A, t=20.1, 90% A and t=25, 90% A.  
Quantification was achieved using MRM scan mode and positive electrospray ionization (ESI). 
The monitored precursor ion → product ion transition for each 12C2-DNS-analyte (dansyl derivatized 
metabolite), was m/z [M+H]+→ m/z 170.10, while the analogues 13C2-DNS- internal standards (ISs) 
were monitored at m/z [M+H]+→ m/z 172.10. A qualifier diagnostic product ion was monitored for each 
12C2-DNS-analyte to confirm its identity, shown in Table 1. The following parameters were optimized: 
turbo spray ion source temperature= 550 ºC, ion spray voltage= 5.5 kV, curtain gas= 30, collision gas= 
9, nebulizer gas= 50, heater gas= 50, entrance potential=10, collision exit potential= 13, total dwell 
time= 20 msec and cycle time=1.4504. The collision energy (CE) and declustering potential (DP) were 
separately optimized for each analyte (Table 1). Data processing was achieved on Analyst software, 
version 1.6.2 (AB Sciex, Concord, ON, Canada) and SPSS software (version 24). 
 
2.6. Metabolite selection 
Based on our previous experience with human urine quantitative analysis [37], we chose 4 
metabolites: valine (VAL), tryptophan (TRP), serine (SER) and ethanolamine (ETNH2). Each met at 
least three of the following criteria: (A) the metabolite is typically present in urine below its upper limit 
of quantification (ULOQ), and does not require additional sample dilution; (B) the metabolite is not 
seen at a concentration below the lower limit of quantification (LLOQ); (C) the metabolite’s 
concentration is known to vary greatly among participant samples regardless of the participant’s 
hydration status; and (D) the average concentration of the metabolite in pooled urine sample was in the 
middle range of the calibration curve.  
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The performance of the single point and relative quantification methods was further challenged 
through the inclusion of sarcosine (SAR) and lysine (LYS), which we have found to be present in urine 
towards the lower end of their linearity ranges. The selection criteria were biased towards the “best 
performing” metabolites. Such bias ensured that the variations in metabolite concentration would reflect 
true differences in performance across different quantification methods. Metabolites that might 
compromise the power of the analysis due to their trace levels (below LLOQ) were excluded, so as 
those that might introduce an error in the comparative study due to their additional sample preparation 
(above ULOQ). 
 
2.7. Metabolite quantification  
A. Multipoint calibration  
Absolute quantification requires the use of calibration and QC samples (Figure 1A). Preparation 
of such solutions was done in accordance with our published protocol [37]. Eight-point calibration 
curves were generated by plotting peak area ratios of 12C2-DNS analytes and 13C2-DNS ISs against the 
corresponding 12C2-DNS analytes concentrations (Table 1). Linear regression equations were generated 
using the sum of least squares with 1/x2 weighing; a factor previously optimized during method 
validation [37]. QC samples were prepared at three different levels; lower QC (LQC), middle QC 
(MQC) and high QC (HQC) (Table 1). 
 
B. Single point calibration 
Raw data generated from Analyst software, version 1.6.2 was reprocessed for single point 
calibration. Since in real practice, each calibration curve point or QC sample can serve as a calibrator 
for analyte quantification (Figure 1A), metabolites were quantified using all calibration points and all 
three QC levels. There are differences in the linearity range optimized for each metabolite based on its 
levels in urine [37]. As such, the concentration of the calibrators are expressed in terms of fold 
concentration to the LLOQ. Calibrators [200×] to [1×], represent the eight calibration solutions, where 
[200×] corresponds to the ULOQ and [1×] represents LLOQ (Table 1). Peak area ratios of 12C2-DNS-
analytes to 13C2-DNS-ISs in calibrators and individual urine samples were the basis for metabolite 
quantification (section 2.8).  
 
C. Semi “Relative” quantification  
Relative quantification was achieved in two sequential steps as previously reported (Figure 1B) 
[27]. In the first step, the selected metabolites were quantified in pooled urine relative to their standards. 
In the second step, the quantified metabolites in pooled urine were used to determine their concentration 
in individual urine samples. For the quantification of metabolites in pooled urine (Step 1), 3 different 
volumes from 12C2-DNS-analytes solution, producing final concentrations equivalent to calibrators 
[133.3×], [83.3×] and [2.67×], were properly diluted to 50 µL with 50% ACN and were separately mixed 
with 50 µL of 13C2- pooled urine sample. The concentrations of the selected 13C2-DNS-urinary 
metabolites were determined using absolute peak area comparison against each 12C2-DNS-analyte 
calibrator (section 2.8). In step 2, 50 µL of 13C2- pooled urine sample were mixed with an equal volume 
of individual 12C2- urine sample (Figure 1B). Quantification of metabolites in individual urine samples 
was also achieved through absolute peak area comparison (section 2.8).  
 
2.8. Statistical data analysis 
Data processing for absolute quantification was conducted using Analyst software, version 
1.6.2. Raw data was further exported to Excel (Microsoft office 2013) for the calculation of metabolite 
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concentrations in single point calibration mode (equation 1). Raw data in relative quantification was 
processed based on equations 2 and 3. The final concentrations of all metabolites were further exported 
to SPSS program (version 24) to create figures.  
        	1:	    . (     ) =     	    	     	(     ) 	× 	    . (           	        )
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3. Results and Discussion  
This work was designed to address four questions in a DIL-LC-MS/MS targeted metabolomic 
workflow used for biomarker qualification. First, if an analytical method has been fully validated using 
multipoint DIL-LC-MS/MS, could metabolites be quantified with similar accuracy and precision, using 
single point calibration? This would substantially reduce instrument time, the number of calibration 
standards, and the QC samples to be prepared. Second, would the choice of the single calibrator point 
(low vs. high and/or proximity to analyte concentration in a sample) affect the accuracy? Third, if the 
DIL-LC-MS/MS method was used with relative quantification, would the knowledge of the dynamic 
range of the mass spectrometer along with the optimization of the derivatization reaction solely suffice 
for the acquisition of data with acceptable accuracy and precision? Finally, would the exclusion of 
individual urine samples from the pooled urine sample compromise the accuracy and precision of 
relative quantification? This is particularly important when new participants are still being recruited 
during the biomarker validation process.  
 
3.1. Multipoint calibration method 
Table 1 summarizes the optimized MS parameters and the linearity ranges [37] of the selected 
metabolites. Figure 2 shows two representative calibration curves for ETNH2 and SER. All eight 
calibration points for all metabolites were within 15% of their respective nominal values, indicating 
acceptable calibration curves [15,14] for quantification (data not shown). Table 2 compiles the accuracy 
and precision of the LQC, MQC and HQC samples, obtained during participant sample analysis. As 
seen in Table 2, all QC samples were within 15% of their respective nominal values. In addition, their 
relative standard deviation (RSD%) was below 15%, indicating that the analytical runs met regulatory 
guidelines during clinical data acquisition [15,14]. Details on the validation process of the multipoint 
calibration method are beyond the scope of this article, however, readers are advised to refer to our 
previously published work [37]. 
Urine samples from seven individuals and a pooled urine sample from five participants were 
analyzed using our previously validated multipoint calibration DIL-LC-MS/MS method [37]. Table 3, 
summarizes the concentrations of the metabolites in these samples. Calculated RSD% demonstrates 
high precision of the measurements (below 15%), with the exception of SER in participant 5 in which 
RSD% was 15.9% (Table 3). The concentration of TRP in participant 3 was above the ULOQ and was 
omitted from the calculations. Similarly, SAR in participant 1 was lower than the LLOQ and data from 
this participant for SAR was excluded (Table 3). As expected, the selected metabolites with the 
exception of SAR and LYS vary greatly in their concentration among the participant samples as well as 
in their distribution within their calibration ranges (Figure 3). 
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3.2. Single point calibration method 
A. Results using QC samples 
Single point calibration was achieved by mathematical manipulation of the raw dataset obtained 
from the multipoint calibration method (equation 1). Similar to multipoint calibration where QC 
samples are used for quality assessment, QC samples were also used to evaluate the performance of the 
eight individual calibration standards as single point calibrators (Table 4). The acceptance criteria 
established for bioanalytical method validation was adopted [14,15], in which accuracy values within 
±15% and RSD% below 15% are deemed acceptable. The performance of single point calibration was 
found inferior to that of the multipoint calibration for LYS, SER and ETNH2, in which 3 out of 8 
calibrators failed to demonstrate acceptable accuracy in at least one QC measurement (Table 4). 
Calibrator [33.3×] resulted in unacceptable accuracy (115.5% and 117.8%) at the LQC level for SER 
and ETNH2, respectively, while in LYS, calibrator [3.3×] resulted in 115.8% accuracy at the MQC 
level. These deviated results would have been anticipated if the observed values for calibrators [33.3×] 
and [3.3×] were different than the calculated values provided by the regression model (Figure 2), which 
was not the case. On the other hand, the accuracy of calibrator [1×] (equivalent to LLOQ) was 
acceptable for all metabolites with the exception of ETNH2, in which accuracies less than 85% were 
obtained for the MQC and HQC levels (Table 4).  
As for the methods’ precision, the criterion in all metabolites was met at all levels, and therefore 
was comparable to multipoint calibration from a validation standpoint (Table 4). However, one 
interesting observation is that the highest RSD% variation for the LQC and HQC in SAR, VAL, TRP, 
ETNH2 and LYS were mostly generated from calibrator [1×] (i.e. LLOQ). This information is valuable 
as it indicates higher chances for imprecision of this calibrator in single point calibration (Table 4). 
Overall, the values generated from multipoint calibration were more accurate and precise that that 
generated from single point calibration (Tables 2 and 4).  
 
B. Results using participants’ samples 
The accuracy and precision of the participants’ data generated using single point calibration was 
evaluated. Metabolites were quantified using individual calibrators [1×] through [200×]. In addition, 
the three QC levels, [166.7×], [83.3×] and [2.7×], were also used for quantification, as any standard 
solution can serve as a calibrator for data acquisition in single-point calibration. Concentration of the 
metabolites generated from multipoint calibration were used as a benchmark and compared against 
those generated using single point calibration. With the exception of ETNH2, all calibrators resulted in 
acceptable accuracies, in which bias values were less than ±15% [15,14] (Figure 4). VAL concentration 
in participant 3, generated from calibrator [33.3×], had the highest deviation from multipoint calibration 
(-14.8% bias) (Figure 4). The average bias values among all participants for SAR, VAL, TRP and LYS 
were the highest with calibrator [3.3×]. Contrary to expectation [39], we have found that the choice of 
calibrator that is in close proximity to the concentration of the analytes in urine samples did not result 
in the most accurate results for low concentration metabolites. 
Another concerning finding for accuracy using single point calibration were observed with 
ETNH2. First, calibrator [1×; i.e LLOQ] resulted in unacceptable accuracy values among the majority 
of the samples, with an average bias of -18.3% (Figure 4). This can be explained by the fact that the 
LLOQ is usually the calibration point in which validation criteria [15,14] allows for wider accuracy 
acceptance limit (±20% instead of ±15%). The second observation is that 7 out of the 10 calibrators 
(excluding [1×]) failed to demonstrate acceptable accuracy in ETNH2 measurements in pooled urine, 
where a maximum bias of -21.3% was observed with calibrator [2.7×] (Figure 4). We could not draw 
an explanation for this observation. In fact, the inadequate performance of most calibrators in measuring 
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ETNH2 had a direct impact on the conclusion of accuracy for single point calibration. As such, we 
cannot exclude the probability that other metabolites [37], not investigated within this study, might not 
be correctly quantified when single point calibration is used. Therefore, it is extremely important to 
investigate the performance of each metabolite, individually, using various calibrators prior to the 
consideration of single point calibration for regular data acquisition. 
We then looked at the precision of single point calibration, and found it inferior to multipoint 
calibration for ETNH2, LYS and SER (Figure 5). Calibrator [1×] resulted in marginally unacceptable 
RSD% of 15.9% and 15.3% for ETNH2 and LYS, respectively. This was not unexpected from this 
LLOQ calibrator, where  higher RSD% values (<20%) are acceptable by the regulatory agencies during 
method validation of multipoint calibration [15,14]. In addition to ETNH2 and LYS, the highest RSD% 
values (still less than 15%) were observed with calibrator [1×] in TRP and SAR (Figure 5). Again, the 
relative inferior precision of this calibrator is important for LYS and SAR, in which a calibration point 
close to the analyte in real samples might not be the optimum point for precise data generation. 
Regardless of the calibrator used, the RSD% values in SER were similar per participant (Figure 5). 
Moreover, most calibrators resulted in unacceptable precision of SER measurements in participants 2 
and 5 (RSD%; 15.2%-17.1%). In general, while the eleven calibrators resulted in acceptable precision 
in the majority of the metabolites in the analyzed samples, the RSD% values were relatively higher in 
single point calibration in comparison with multipoint calibration (Figure 5)  
 
3.3. Relative quantification 
We tailored our validated LC-MS/MS method [37] to quantify metabolites in a relative mode 
using equations 2 and 3 [27]  (Figure 1B), rather than the use of 13C2-isotopic form as an internal 
standard (Figure 1A). We hypothesized that the proximity of metabolites concentrations in pooled urine 
sample to that of the spiked 12C2-DNS-analytes could also influence the accuracy and precision of the 
measurements. 13C2-DNS-pooled urine was first quantified against 12C2-DNS-analytes solution. The 
solutions were mixed at equal volumes, however, the concentration of the standard solution was varied 
to produce high, medium and low calibrators; [133.3×], [83.3×] and [2.7×]. Following the quantification 
of metabolites, pooled urine aliquots were then separately mixed with equal volumes of 12C2-derivatized 
individual urine samples (Figure 1B).  
We were also concerned that the exclusion of individual urine samples from the pooled urine 
sample might compromise the accuracy and precision of relative quantification. This is particularly 
important when new participants are still being recruited during the biomarker validation process. In 
fact, the inability to pool all samples prior to analysis, for instance due to different times and locations 
of analysis, has been proposed as a potential impediment to the use of pooled control urine in large scale 
metabolomics [40]. As such, we created a sample pooled from five participants and left two out for later 
individual comparison. The pooled urine was then used to quantify all individual urine samples, 
including the excluded samples.  
Relative quantification was very precise but showed inaccuracies in measurements more than 
single point calibration (Figure 6). With the exception of VAL and ETNH2, all metabolites had at least 
one calibrator with inaccurate data (greater than ±15% deviation from multipoint calibration). 
Calibrators [133.3×] and [83.3×] failed to produce accurate quantitative data (i.e. within ± 15%) for 
SAR, LYS, and TRP in at least 3 out of 8 samples. On the other hand, the lowest calibrator, i.e., [2.7×] 
was the only standard producing accurate measurements for LYS, SAR and TRP in all urine samples 
(Figure 6). While this observation can be justified by the low concentration of LYS and SAR in 
individual and pooled urine, an extrapolation to TRP, a widely distributed metabolite among patients 
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and its linearity range (Figure 3), was not applicable. Finally, none of the tested calibrators produced 
accurate results in SER measurements in 6 out of 8 samples (Figure 6).   
In contrast to accuracy, precision of relative quantification was comparable to that of multipoint 
calibration. As shown in the error bars of Figure 6, all measurements were deemed precise with a RSD% 
of less than 15%. An exception was observed with calibrators [2.7×] and [133.3×] that resulted in high 
RSD % (18.3% and 16%) in participants 7 and 2, respectively during SER quantification. Interestingly, 
unlike single point calibration, participant 7 consistently demonstrated the highest RSD% in all 
metabolites and with all calibrators. This observation could be attributed to the exclusion of this 
participant from the pooled urine sample. Therefore, the pooled matrix might not reflect the real matrix 
effect experienced within this participant. However, since this observation was not consistent with 
participant 6, who was also excluded, random error could also justify the higher dispersion of RSD%. 
The limited number of excluded participant samples hinders the decisive conclusion on such 
observation. 
 
4. Conclusion 
Our comparison of single point calibration and relative quantification to a multipoint validated 
DIL-LC-MS/MS method demonstrated shortcomings. We initially hypothesized that single point 
calibration would serve as an excellent substitute to multipoint calibration in the selected analytes and 
would not necessitate further testing of other metabolites [37]. Unfortunately, this hypothesis was not 
correct due to inconsistent performance across all investigated metabolites. Therefore, we recommend 
that if single point calibration is to be used for clinical data acquisition, it requires assessment on case-
by-case basis. This would require investigation of the quality of the data for each metabolite using larger 
cohorts of samples. In addition, the results herein cannot be extrapolated to the same metabolites when 
a different derivatizing reagent or matrix is employed.  
The calibration mode had more influence on the accuracy of the data than its precision. 
Surprisingly, we did not find the accuracy of single point calibration to be dependent on the closeness 
of the analyte concentration to that in the sample. Further, the inaccuracy with ETNH2 emphasizes that 
results from one calibrator might not be applicable to other metabolites beyond this study. In general, 
we recommend against the use of the LLOQ, even if the metabolite of interest lies within the lower 
range of the linear curve. In addition, unless established via experimentation that a specific calibrator is 
inaccurate and/or imprecise, any calibrator could theoretically serve as an adequate single point 
calibration standard for quantification, regardless of its concentration proximity to the metabolite of 
interest.  
In regard to relative quantification, this method was less accurate in comparison to single point 
calibration. However, It has value in preliminary semi-quantitative analysis (e.g. screening metabolites 
for possible biomarker targets), which then would require validation. One possible explanation is the 
dependence of the results on the values obtained from pooled urine. Errors within the pooled urine 
metabolite quantification are further augmented in individual samples. Therefore, the quantification of 
the metabolite in the pooled urine sample represents the most critical step, upon which the accuracy of 
the rest of the analyses are dependant. For instance, in SAR, LYS, VAL and TRP, the calibrator that 
resulted in the most accurate quantification values in pooled urine was also associated with the highest 
accuracy in participant samples. Using the absolute peak areas can also be another potential source of 
error, where the matrix in which the pooled urine sample is quantified, is different from that of the 
individual urine samples. Exclusion of samples from the pooled matrix can also be a potential source 
of lower quality data [40]. 
10 
 
Finally, this study was biased towards metabolites whose concentrations were already known to 
typically fall within the constructed calibration curve. While an inconsistent difference in the 
investigated quantification methods was demonstrated, such difference is expected to be further 
amplified in situations with highly concentrated metabolites that typically require dilution (e.g. 
histidine, alanine and glycine) [37]. The same would apply to metabolites which frequently fall below 
their LLOQ (e.g. 1-methylhistamine) [37]. While a general conclusion on relative quantification or 
single point calibration cannot be made, based on our study findings, we advise the analytical 
community to exercise caution and rigor assessment when employing single point calibration or relative 
quantification for targeted urine metabolomics. 
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Table 1: The MS and regression parameters of the investigated dansylated metabolites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Metabolites quantified as DNS derivatives, 1[200×] corresponds to the upper limit of quantification (ULOQ) and [1×] represents the lower limit of 
quantification (LLOQ),  2 Collision energy, 3 Declustering potential, 4 Quantifier product ion= m/z 170.1 
 
 
 
 
 
 
 
 
 
Analyte* Sarcosine 
(SAR) 
Valine 
(VAL) 
Tryptophan 
(TRP) 
Serine 
(SER) 
Ethanolamine 
(ETNH2) 
Lysine 
(LYS) 
Regression equation 1.63E-03x+ 3.12E-04 
1.63E-03x+ 
4.46E-04 
7.18E-04x+ 
3.37E-04 
3.77E-04x + 
6.20E-04 
3.41E-04x+ 
1.71E-03 
3.44E-04x+ 
1.40E-04 
r2 0.9974 0.997 0.997 0.998 0.998 0.9971 
Calibration points [× of 
LLOQ]1 
Concentrations ng/mL 
ULOQ [200×] 
[133.3×] 
[75×] 
[66.7×] 
[33.3×] 
[10×] 
[3.3×] 
LLOQ [1×] 
HQC [166.7×] 
MQC [83.3×] 
LQC [2.7×] 
375 
250 
187.5 
125 
62.5 
18.75 
6.25 
1.875 
312.5 
156.25 
5 
750 
500 
375 
250 
125 
37.5 
12.5 
3.75 
625 
312.5 
10 
1500 
1000 
750 
500 
250 
75 
25 
7.5 
1250 
625 
20 
3000 
2000 
1500 
1000 
500 
150 
50 
15 
2500 
1250 
40 
3000 
2000 
1500 
1000 
500 
150 
50 
15 
2500 
1250 
40 
4800 
3200 
2400 
1600 
800 
240 
80 
24 
4000 
2000 
64 
CE2 27 30 39 29 32 38 
DP3 66 75 60 70 55 80 
Q1 323.0 351.1 438.2 339.1 295.1 613.2 
Q34 Qualifier product ion 157.1 336.1 130.1 324.1 157.1 234.1 
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Table 2: Inter-day accuracy and precision of QC samples of the multipoint calibration method during participant sample analysis 
 
 
 
 
*n=4 
**ng/ml 
1 lower quality control level 
2 middle quality control level 
3 third quality control level  
  
 LQC*1                                MQC*2 
 
                       HQC*3 
          
 Nominal** Mean**± SD RSD (%) 
Accuracy 
(%) Nominal
** Mean** ±SD RSD (%) 
Accuracy 
(%) Nominal
** Mean **± SD RSD (%) 
Accuracy 
(%) 
SAR 5 5.01±0.25 5.03 100.2 157 163.38±2.84 1.74 104.0 323 306.63±10.19 3.32 98.0 
VAL 10 10.20±0.39 3.84 102.0 313 324.25±4.35 1.34 103.5 625 617.5±26.6 4.31 98.9 
TRP 20 20.00±0.67 3.37 100.0 625 658.75±16.09 2.44 105.3 1250 1245±58.02 4.66 99.8 
SER 40 41.38±1.65 3.98 103.7 1250 1290.00±18.26 1.42 103.5 2500 2485±110.3 4.44 99.4 
ETNH2 40 40.80±1.42 3.47 102.0 1250 1297.50±17.08 1.32 103.8 1250 2455±71.88 2.93 98.2 
LYS 64 63.98±2.14 3.35 100.0 2000 2072.50±23.63 1.14 104.0 4000 4032.5±133.8 3.32 100.8 
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Table 3: Concentrations of metabolites in the analyzed urine samples using multipoint calibration 
   
 
Metabolite 
  
SAR VAL TRP SER ETNH2 LYS 
  Mean1 27.52 723.2 3882.7 14176.0 6720.0 1712.0 
Participant 1 SD 0.2 37.8 121.2 871.8 263.4 83.1 
 RSD% 0.7 5.2 3.1 6.1 3.9 4.9 
 Mean1 50.7 3637.3 13557.3 34933.3 26293.3 3674.7 
Participant 2 SD 1.8 193.6 571.6 3841.1 937.5 202.6 
 RSD% 3.5 5.3 4.2 11.0 3.6 5.5 
 Mean1 291.7 7056.0 30506.72 41386.7 32640.0 17760.0 
Participant 3 SD 4.7 399.7 805.3 2178.2 1270.0 1269.9 
 RSD% 1.6 5.7 2.6 5.3 3.9 7.2 
 Mean1 137.9 6080.0 20533.3 40160.0 41760.0 3114.7 
Participant 4 SD 0.9 296.3 184.8 3187.9 1049.2 345.2 
 RSD% 0.7 4.9 0.9 7.9 2.5 11.1 
 Mean1 48.4 3477.3 7429.3 26933.3 16586.7 3301.3 
Participant 5 SD 1.8 147.8 451.5 4294.2 756.1 309.6 
 RSD% 3.6 4.3 6.1 15.9 4.6 9.4 
 Mean1 70.5 3440.0 9888.0 18293.3 28800.0 3296.0 
Participant 6 SD 1.9 69.7 242.1 1854.4 576.9 194.0 
 RSD% 2.8 2.0 2.5 10.1 2.0 5.9 
 Mean1 97.8 3018.7 5776.0 26293.3 18773.3 5130.7 
Participant 7 SD 3.8 92.4 146.6 488.8 402.7 124.3 
 RSD% 3.9 3.1 2.5 1.9 2.1 2.42 
 Mean1 111.2 4261.3 15173.3 31146 25333.3 6277.3 
Pooled Urine  SD 6.3 197.5 456.6 2916.8 1512.3 470.4 
  RSD% 5.6 4.6 3.0 9.4 5.9 7.5 
1 ng/mL, n=3, 2 values below lower limit of detection or above upper limit of quantification 
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 Table 4: Inter-day accuracy and precision using single point calibration  
1bolded values indicate accuracy measurements out of the acceptable range ±15%, italic and underlined 
values indicate the highest precision values among calibrators 
2 n=4 
  
   Calibrator 
Metabolite QC level1  [200×] [133.3×] [75×] [66.7×] [33.3×] [10×] [3.3×] [1×] 
 LQC % Accuracy 101.6 96.3 96.8 97.8 109.7 98.3 109.2 98.2 
  RSD% 3.1 5.8 4.1 3.5 5.8 5.4 2.5 7.6 
SAR MQC %  Accuracy 105.1 99.6 100.1 101.2 113.4 101.6 113.0 101.5 
  RSD% 1.8 2.8 1.7 1.7 2.8 2.5 4.8 4.5 
 HQC %  Accuracy 98.8 93.7 94.1 95.2 106.7 95.6 106.2 95.5 
  RSD% 2.6 5.4 3.7 3.0 5.5 5.1 2.1 7.4 
 LQC %  Accuracy 105.1 99.2 98.1 101.0 111.1 100.3 113.0 97.9 
  RSD% 2.4 5.5 3.8 2.6 4.8 3.7 5.1 6.1 
VAL MQC %  Accuracy 105.2 99.3 98.1 101.1 111.2 100.4 113.2 98.0 
  RSD% 1.2 4.0 2.3 1.2 3.3 2.2 6.2 4.6 
 HQC %  Accuracy 100.1 94.5 93.4 96.1 105.8 95.5 107.6 93.2 
  RSD% 3.7 6.7 5.1 3.9 6.1 5.0 4.6 7.3 
 LQC %  Accuracy 108.3 102.7 103.1 104.2 115.5 103.9 111.2 96.6 
  RSD% 3.6 3.9 3.9 4.0 4.5 4.2 5.0 4.3 
SER MQC %  Accuracy 104.1 98.7 99.2 100.2 111.1 99.9 107.0 92.9 
  RSD% 1.1 1.5 1.5 1.7 2.5 2.0 4.2 2.1 
 HQC %  Accuracy 100.4 95.2 95.6 96.6 107.1 96.3 103.0 89.6 
  RSD% 4.0 4.9 4.8 5.1 6.0 5.5 2.4 5.6 
 LQC %  Accuracy 102.3 94.9 96.6 97.6 109.2 98.9 109.4 97.3 
  RSD% 2.8 3.3 3.0 3.0 3.1 3.2 5.0 5.6 
TRP MQC %  Accuracy 106.7 98.9 100.7 101.8 113.8 103.0 114.1 101.4 
  RSD% 2.6 1.7 2.0 3.4 1.8 1.7 6.3 3.3 
 HQC %  Accuracy 100.8 93.6 95.2 96.1 107.6 97.4 107.7 96.0 
  RSD% 4.7 6.2 5.4 3.9 5.8 6.1 2.2 9.2 
 LQC %  Accuracy 111.5 106.5 106.0 105.7 117.8 103.8 111.9 90.1 
  RSD% 3.0 2.0 2.2 2.9 2.0 2.5 3.2 9.3 
ETNH2 MQC %  Accuracy 105.0 100.3 99.8 99.6 111.0 97.8 105.4 84.9 
  RSD% 1.8 1.5 2.3 1.6 1.4 1.3 2.0 10.1 
 HQC %  Accuracy 99.3 94.9 94.5 94.2 105.0 92.5 99.7 80.5 
  RSD% 2.4 4.4 5.5 2.6 4.4 3.1 2.2 13.3 
 LQC %  Accuracy 98.0 96.0 94.3 96.3 108.1 97.7 110.6 99.6 
  RSD% 1.9 4.3 2.1 1.9 4.3 4.7 4.3 6.5 
LYS MQC %  Accuracy 102.6 100.5 98.7 100.8 113.2 102.2 115.8 104.2 
  RSD% 2.7 2.0 0.9 1.4 2.1 2.5 5.9 4.3 
 HQC %  Accuracy 99.7 97.7 96.0 98.0 110.1 99.4 112.5 101.5 
  RSD% 2.6 5.9 3.7 3.3 6.0 6.3 3.4 8.1 
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Figure 1. Quantitative platforms in DIL-LC-MS/MS; (A) single and multipoint calibration and (B) relative quantification. Pooled 
surrogate urine is prepared from 7 pooled urine samples processed as described under 2.3. standards derivatization. 
 
 
 
B A 
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Figure 2: representative calibration curves generated from the multipoint calibration method for the 
quantification of ETNH2 and SER 
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Figure 3: Concentrations of investigated metabolites in patients urine samples, data normalized to each metabolite’s ULOQ. Patients 
are abbreviated as P followed by their ID number, PU is pooled urine sample. 
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Figure 4: Box and whisker plots of inter-day bias of metabolites measurements as obtained with single point 
calibration. Bias is defined as % deviation from multipoint calibration calculated using each calibration solution 
(1×-200×) and QC sample (3 levels) as single point calibrators, equation 1, Y axis represent the absolute bias values 
calculated using 8 urine samples each processed in triplicates, the upper and lower whiskers represent higher and 
lower bias values, respectively. The box represents the interquartile range and the median is expressed through the 
vertical line within in the box. Participants are represented by “P”, PU is pooled urine 
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Figure 5: Box and whisker plots of metabolites measurements inter-day precision as obtained with multipoint 
calibration (using regression equation, Table 1) and single point calibration (using each calibration solution [1×] 
to [200×] and QC solutions (3 levels) as calibrators, equation 1). Y axis represent the RSD% ranges obtained from 
8 urine samples each processed in triplicates; the upper and lower whiskers represent higher and lower RSD% 
ranges, respectively. The box represents the interquartile range of RSD% values and the median is expressed 
through the vertical line within in the box. Participants are represented by “P”, while “PU” stands for pooled urine 
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Figure 6: Accuracy and precision of relative quantificaiton, bar hight respresent method accuracy, in 
comparison to multipoint calibration, errror bars represent RSD%, n=3 
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